First published 9/30/2026, 8:27:15 AM · Last updated 9/30/2026, 8:27:15 AM

Real world effectiveness and safety of durvalumab based first line therapy in advanced biliary tract cancer: results from the prospective German LIVER-R cohort

Peer-reviewed journal article reporting prospective cohort results from Germany on the effectiveness and safety of durvalumab-containing first-line treatment for advanced biliary tract cancer; the source excerpt supplies no numeric results or outcomes. Additional study details were not included in the provided source data.

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 4/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article presents real-world clinical outcome data for a systemic therapy regimen in advanced biliary tract cancer.

Location

Sources

Real world effectiveness and safety of durvalumab based first line therapy in advanced biliary tract cancer: results from the prospective German LIVER-R cohort

Report an issue